

**THE CHALLENGE OF INFRAPOPLITEAL DISEASE:
CHARACTERISTICS,
RESTENOSIS AFTER ENDOVASCULAR REVASCULARIZATION AND
REVIEW OF SEVERAL NEW TECHNOLOGIES**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2023

All rights reserved, including the right of reproduction
in whole or in part in any form.

REFERENCES (FIRST AND LAST PAGES)

1. Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc*. 2018 Dec 18;7(24):e011245.
2. Secemsky EA. Have we gotten to the final word on paclitaxel safety? *Transcatheter Cardiovascular Therapeutics (TCT) 2022*, Sept 17. [Internet. Accessed 2022, Dec.] Available at: <https://www.tctmd.com/slide/have-we-gotten-final-word-paclitaxel-safety-0>.
3. Beckman JA, Schneider PA, Conte MS. Advances in revascularization for peripheral artery disease: revascularization in PAD. *Circ Res*. 2021 Jun 11;128(12):1885-1912. doi: 10.1161/CIRCRESAHA.121.318261. Epub 2021 Jun 10. PMID: 34110904.
4. Spiliopoulos S, Kitrou PM, Brountzos EN. Revisiting endovascular treatment in below-the-knee disease. Are drug-eluting stents the best option? *World J Cardiol*. 2018 Nov 26; 10(11):196-200.
5. Yost ML. *The cost of critical limb ischemia (CLI). Why is the disease so costly?* 2019. Beaufort (SC):THE SAGE GROUP; 2019.
6. Mustapha JA, Finton SM, Diaz-Sandoval LJ, Saab FA, Miller LE. Percutaneous transluminal angioplasty in patients with infrapopliteal arterial disease: systematic review and meta-analysis. *Circ Cardiovasc Interv*. 2016 May;9(5):e003468.
7. Shishehbor MH, Hammad TA. Treatment of infrapopliteal disease in critical limb ischemia: beyond angioplasty. *Circ Cardiovasc Interv*. 2016 May;9(5):e003882
8. Zeller T, Baumgartner I, Scheinert D, et al; IN.PACT DEEP Trial Investigators. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. *J Am Coll Cardiol*. 2014 Oct 14;64(15):1568-76.
9. Wu R, Yao C, Wang S, et al. Percutaneous transluminal angioplasty versus primary stenting in infrapopliteal arterial disease: a meta-analysis of randomized trials. *J Vasc Surg*. 2014 Jun 1; 59(6):1711-20.
10. Lo RC, Darling J, Bensley RP, et al. Outcomes following infrapopliteal angioplasty for critical limb ischemia. *J Vasc Surg*. 2013 Jun 1;57(6):1455-64.
11. Faglia E, Mantero M, Caminiti M, et al. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. *J Intern Med* 2002;252:225-32.
12. Saqib NU, Domenick N, Cho JS, et al. Predictors and outcomes of restenosis following tibial artery endovascular interventions for critical limb ischemia. *J Vasc Surg*. 2013 Mar;57(3): 692-9.

187. R³ Vascular. Advantage. [Internet. Accessed 2022, Oct.] Available at: <https://www.r3vascular.com/about>.
188. Varcoe RI. Long term results and a glimpse into the future with bioresorbable scaffolds for BTK? Presentation at LINC 2022. [Internet. Accessed 2022, Oct.] Available at: https://nmsuitelinc2020.s3.amazonaws.com/1516_Ramon_Varcoe_28_01_2020_Room_5_-_Global_Expert_Exchange.pdf?AWSAccessKeyId=AKIAW6WNXN5VMODX4QSF&Expires=1665685036&Signature=rGwF0%2Fb5Rxe4SJ4iYUZRVRndsVM%3D. Link no longer functioning. Slides available on request.
189. Meril Life Sciences. Clinical Program. [Internet. Accessed 2022 Oct.] Available at: <https://www.merillife.com/assets/pdfs/clinical-data/credence-btk-1-study-1601879609pdf.pdf>.
190. Kyoto Medical Planning Co. Remedy biodegradable peripheral stent. [Internet. Accessed 2022, Oct.] Available at: <https://www.kyoto-mp.co.jp/en/remedy.html>.
191. ClinTrials.gov. The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery (Efemoral I). [Internet. Accessed 2022, Oct.] Available at: <https://clinicaltrials.gov/ct2/show/NCT04584632>.

CONTACT INFORMATION

Mary L. Yost
President
Telephone (404) 520-6652
yost@thesagegroup.us